CLINICAL_TRIALS
trial_result
· 2014-06-20
Clinical Trial Update: Flibanserin Evaluation Over 28 Additional Weeks in Hypoactive Sexual Desire Disorder [Phase 3]
Summary
This update reports the results of an additional 28 weeks of evaluation in a Phase 3 trial of flibanserin for hypoactive sexual desire disorder.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Sprout Pharmaceuticals, Inc | Conditions: Sexual Dysfunctions, Psychological | Phase 3 | Status: COMPLETED | Results posted: 2014-06-20